

10/561713

Express Mail No. EV629077400US
Date of Deposit: December 21, 2005
PATENT

SLR:dm 12/20/05 5585-72843-01 464161 RCD/P102877US1

IAP20 RECEIVED PTO 21 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Diane Clayton and Rebecca Rutter

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: INFLAMMATORY DISEASE
TREATMENT

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-72843-01

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a

10/561713

IAP20 REG 21 DEC 2005

Express Mail No. EV629077400US
Date of Deposit: December 21, 2005
PATENT


SLR:dm 12/20/05 5585-72843-01 464161 RCD/P102877US1

fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	5585-72843-01
	Application Number	1008361713
	Filing Date	December 21, 2005
	First Named Inventor	Clayton
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,444,054	08/22/1995	Garleb et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 699 437 A1	03/06/1996	Prospa B.V.
		WIPO	WO 98/37874 A1	09/03/1998	AstaCarotene AB
		WIPO	WO 01/24787 A1	04/12/2001	AstaCarotene AB
		WIPO	WO 02/102394 A2	12/27/2002	Neptune Technologies & Bioresources Inc.
		WIPO	WO 03/082313 A1	10/09/2003	Alcon, Inc. and Biodar Ltd.
		WIPO	WO 2004/080196 A2	09/23/2004	Advanced Bionutrition Corporation
		WIPO	WO 2004/082399 A2	09/30/2004	Advanced Bionutrition Corporation

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Guerin et al., "Haematococcus astaxanthin: Applications for Human Health and Nutrition," <i>Trends in Biotechnol.</i> 21:210-216 (2003).
		Murthy et al., "Omega-3 Fatty Acids as Anti-Inflammatory Agents: A Classical Group of Nutraceuticals," <i>J. Nutraceuticals</i> 2:53-72 (1999).
		Wang et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit <i>Helicobacter pylori</i> Infection in BALB/cA Mice," <i>Antimicrob. Agents Chemother.</i> 44:2452-2457 (2000).

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.